Archives

FDA Breakthrough Device Designation is granted to devices that have the potential to offer a “more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases.” [...]

Renowned heart failure cardiologist, Dr. William T. Abraham, makes this move to V-Wave after more than 16 years as Director of the Division of Cardiovascular Medicine at The Ohio State [...]

RELIEVE-HF is a global, randomized, controlled, double-blinded, 500 patient pivotal study to evaluate the safety and effectiveness of V-Wave’s novel therapy. V-Wave Ltd. announced today that it [...]

$70M Series C financing led by Deerfield Management; V-Wave also announced upcoming launch of the RELIEVE-HF pivotal study. V-Wave Ltd., an Israel-based company that has developed a proprietary, [...]